The study end-point was 1) new anemia (<12.0 g/dl for women and <13.0 g/dl for men) for non-anemic patients, and 2) decreased hemoglobin levels greater than 1 g/dl and/or initiation of treatment including iron supplementation and EPO-stimulating agents for anemic patients. Here, EPO is linked to anemia (phenotype).